Journal profile · ONCOLOGY
Hepatic Oncology
ISSN 2045-0923 · eISSN 2045-0931 · Future Medicine Ltd · United Kingdom
Hepatic Oncology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2 (journal website); fully open access; APC about USD 2,195; median 181 days to acceptance (12 articles, last 24 months); acceptance rate 57% (journal website); 8 articles in 2025; indexed in ESCI and Scopus; the journal's website says submissions are paused or closed.
The journal's website says submissions are paused or closed: Hepatic Oncology is no longer accepting submissions on this site. Source ↗Publisher website ·
Scope
Aims, scope and focus
Hepatic Oncology is published by Future Medicine Ltd and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment and Cholangiocarcinoma and Gallbladder Cancer Studies, together about 52.2% of its articles. Its main subfields are Hepatology. (generated from OpenAlex topic counts and CAS ranking data)
Hepatic Oncology is no longer accepting submissions on this site. Our in-house Commissiong Editors will be in contact with authors with submissions currently under review. All published content to date will remain available online. For prospective submissions, please reach out to Publisher Sophie Aves ( Sophie.Aves@tandf.co.uk), who will be able to suggest suitable alternative journals for your content. Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Studies on all types of primary and secondary hepatic cancers, including hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, fibrolamellar carcinoma and mesenchymal cancers of the liver Clinical trials in hepatic oncology Diagnosis and imaging Epidemiology Palliative care Pathogenesis Pathology Pediatrics Pharmacoeconomics, outcomes and comparative effectiveness research Prognosis Risk factors Staging Surveillance Therapy, including surgery, chemotherapy, chemoembolization, ablation, radiotherapy, hormonal and biological therapies Translational research and biomarker studies
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Hepatocellular Carcinoma Treatment and PrognosisMedicine28.8%
- Liver Disease Diagnosis and TreatmentMedicine13%
- Cholangiocarcinoma and Gallbladder Cancer StudiesMedicine10.5%
- Liver physiology and pathologyMedicine5.5%
- Cancer Mechanisms and TherapyMedicine4.7%
- Hepatitis B Virus StudiesMedicine4.3%
- Pancreatic and Hepatic Oncology ResearchMedicine3.4%
- Gallbladder and Bile Duct DisordersMedicine3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCEmbasePublisher website
Other: Research Alert
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.7Publisher website ·
- CiteScore 2026-06
- 1.8LetPub ·
- CiteScore (publisher) 2025
- 1.8Publisher website ·
- SJR 2026-06
- 0.41LetPub ·
- SJR (publisher) 2025
- 0.41Publisher website ·
- SNIP 2026-06
- 0.42LetPub ·
- SNIP (publisher) 2025
- 0.42Publisher website ·
- h-index
- 26OpenAlex ·
- i10-index
- 69OpenAlex ·
- 2-year mean citedness
- 2.59OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 8LetPub ·
- Downloads per year (publisher)
- 37,000Publisher website ·
Articles by year OpenAlex count · 210 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 5 | 5 | 0 |
| 2025 | 8 | 8 | 32 |
| 2024 | 4 | 4 | 12 |
| 2023 | 4 | 4 | 32 |
| 2022 | 4 | 4 | 11 |
| 2021 | 8 | 8 | 95 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
181 daysMedian, submission to acceptance · P25–P75 141 days – 218 days
- Acceptance to online
- median 15 days (12 articles)
- Submission to online
- median 199 days
- Sample
- 12 articles with submission and acceptance dates (14 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 13 weeksLetPub ·
- Acceptance rate (publisher)
- 57%Publisher website ·
- Submission to first decision
- 44 daysPublisher website ·
- Submission to publication (journal-reported)
- about 13 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,195 | Yes | CC BY-NC-ND | |
| OpenAlex | USD 1,415 | — | — | |
| LetPub | USD 1,415 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- research articleResearch Article | Published online: 12 Sep 2026Length not stated
- review articleReview Article | Published online: 17 Jun 2026Length not stated
Policy excerpts from the journal's websiteAuthorship, Publication ethics, Open access, Peer review
- Authorship
Authors must comply with the journal's Disclosure & Conflict of Interest Policy and major publishing guidelines including ICMJE and GPP3. Model summary
authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3
Source ↗Publisher website ·- Publication ethics
Disclosure & Conflict of Interest Policy; ICMJE; GPP3 compliance required Model summary
authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3
Source ↗Publisher website ·- Open access Open access
Open access journal; only publishes open access articles. Model summary
Hepatic Oncology is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, not just those with e…
Source ↗Publisher website ·- Peer review
All articles subject to independent review by a minimum of three independent experts. Model summary
with all articles subject to independent review by a minimum of three independent experts
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Future Medicine Ltd
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2045-0923
- Electronic ISSN
- 2045-0931
- Latest issue on the website
- Volume 13, Issue 1 (2026)
- Official links
FAQ
Frequently asked questions about Hepatic Oncology
What CAS zone is Hepatic Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Hepatic Oncology is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Hepatic Oncology?
The journal's website gives an impact factor of 2 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 1.8, h-index 26.
How long does peer review take at Hepatic Oncology?
Based on the dates recorded on 12 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 181 days (interquartile range 141–218 days); authors report an average review time of about 13 weeks; the journal's website gives an acceptance rate of 57%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Hepatic Oncology?
According to LetPub and DOAJ records, Hepatic Oncology is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science, PMC and Embase; that list has not been checked against each database.
Is Hepatic Oncology open access, and what is the APC?
Hepatic Oncology is a fully open-access journal. APC about USD 2,195.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .